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Symptomatic hyponatremia with 
hypoxia is a medical emergency
JP Kokko1
Patients presenting with the combined finding of severe symptomatic 
hyponatremia and hypoxia have such high mortality rates that they 
should be admitted to an intensive care unit and intubated sooner rather 
than later. Without delay, these patients need rapid correction of their 
serum sodium by 8–10 mequiv. per liter and an increase in their partial 
pressure of arterial oxygen to values above 70 mm Hg.
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Hyponatremia is a frequent electro-
lyte abnormality among hospitalized 
patients. In general, it is classified as 
acute (less than 48 hours in duration) 
versus chronic (more than 48 hours in 
duration). It is further characterized as 
asymptomatic versus symptomatic (agi-
tation, depressed sensorium, grand mal 
seizures). Th is simple, albeit superfi cial, 
classifi cation is important, as it suggests 
an appropriate therapeutic approach to a 
given patient. Before the 1980s, many of 
us who were in clinical practice felt that 
if we saw a laboratory abnormality, it 
should be corrected rapidly. However, it 
was becoming evident that patients with 
symptomatic hyponatremia had an unac-
ceptably high mortality rate whether 
they were left untreated or whether 
their sodium concentration was rapidly 
corrected. In a classic paper published 
in 1981,1 Kleinschmidt-DeMasters and 
Norenberg reported an experimental 
study in rats that was based on their pre-
vious clinical experience showing that 
central pontine myelinolysis (CPM) is an 
‘iatrogenic disorder’ caused by rapid cor-
rection of hyponatremia. Although their 
conclusion that CPM is an iatrogenic 
disorder was correct, it should be noted 
that in their experiments the rats’ serum 
sodium concentration was rapidly cor-
rected from 106.3 to 151.8 mequiv. per 
liter with the use of hypertonic saline. 
Similar fi ndings of CPM could not be 
duplicated by Ayus and colleagues2 
when hyponatremia in their rats was 
increased by 14–25 mequiv. per liter in 
the fi rst 24 hours, that is, not overcor-
rected rapidly to values above normal. 
However, physicians are taught not to 
harm their patients, and therefore the 
fear of CPM caused such concern that 
many physicians became afraid to 
treat symptomatic hyponatremia, even 
when they recognized that failure to 
treat was associated with high mortal-
ity rates. Th is conservative view against 
rapid correction of plasma sodium con-
centration was supported by a careful 
paper by Sterns,3 in which he observed 
among his 62 patients that the previ-
ously noted high mortality rates with 
symptomatic hyponatremia were not 
nearly as high as some of the literature 
then suggested if the low sodium con-
centration was corrected at low versus 
high rates. Nevertheless, many patients 
were still dying when symptomatic 
hyponatremia was left untreated and 
allowed to correct with spontaneous 
water diureses. Th is led Kidney Interna-
tional to devote a “Nephrology Forum” 
to “Treating hyponatremia: damned if 
we do and damned if we don’t,” in which 
Berl described being presented with two 
patients with hyponatremia, one who 
developed CPM following rapid cor-
rection of serum sodium concentration 
and one who died in the absence of any 
therapeutic interventions to correct her 
hyponatremia.4 We now understand 
that much heterogeneity exists among 
patients with hyponatremia. Some 
patients will tolerate a relatively con-
servative approach, whereas others are at 
high mortality risk if their symptomatic 
hyponatremia is not corrected rapidly. 
Many clinicians have made important 
contributions to this area; perhaps the 
studies of Ayus, Arieff , and their col-
leagues are most direct in pointing out 
that the patients at highest risk are the 
ones with the combined fi nding of symp-
tomatic hyponatremia and hypoxia.5–7 It 
should be noted that neither the early 
clinical observations (before 1992) nor 
animal studies addressed the possible 
adverse eff ect of hypoxia on outcomes in 
symptomatic hyponatremia. To under-
stand why hypoxia is a severe comorbid 
factor requires a paragraph on brain cell 
volume regulation.
Essentially all cells have the capacity 
to regulate their volume. Th e regulation 
of cell volume by the brain cells is criti-
cally important because acute swelling 
of the brain cells is limited by the fi xed 
skull, which will cause pressure necrosis 
and/or transtentorial herniation. On the 
other hand, rapid shrinkage in response 
to an external hypertonic gradient can 
cause adverse cellular events including 
putative disruption of controlled mye-
lin synthesis and degradation. Cell vol-
ume regulation has been studied more 
extensively when cells are challenged to 
protect their volume by exposure to a 
hypo-osmotic external milieu than when 
they are exposed to a hypertonic envi-
ronment such as a rapid rise in plasma 
sodium concentration. When cells are 
exposed to a hypo-osmotic environment 
(hyponatremia), they swell unless there 
is an appropriate outward movement 
of intracellular solutes. Th is is largely 
accomplished by activation of leak path-
way channels that initially allow outward 
diff usion of potassium and chloride and 
later allow outward diff usion of organic 
solutes. It is beyond the scope of this 
Commentary to review these processes; 
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the interested reader is directed to an 
excellent review of this topic by Pas-
antes-Morales and colleagues.8 Many 
biologic regulatory processes are not 
symmetric. This certainly is the case 
when cellular processes are activated to 
protect the volume of cells exposed to 
a hypertonic milieu that would tend to 
shrink them. Under these circumstances 
the cell must gain net solute against elec-
trochemical gradients and requires much 
more oxygen-dependent energy than is 
provided by activation of outward leak 
pathway channels. Th us it is evident that 
conditions in which oxygen availability 
is limited are just those conditions in 
which cells are unable to have suffi  cient 
inward transport rates of solutes to pro-
tect against cell shrinkage.
As they report in this issue,9 Ayus, 
Armstrong, and Arieff have carried 
out an important series of studies that 
extends many of their previous obser-
vations. Th ey show in three groups of 
rodents that hypoxia interferes with 
normal brain cell volume adaptation in 
response to hyponatremic challenges. In 
hyponatremic animals, hypoxia aggra-
vated cerebral edema, decreased cerebral 
perfusion, and led to histologic abnor-
malities in the cerebellum, thalamus, 
reticular formation, and basal ganglia.9 
Many of these histologic fi ndings are 
similar to those that have been noted 
previously to occur when hyponatremia 
has been rapidly corrected. It is interest-
ing that many of these histologic abnor-
malities were not seen when hypoxia 
was not present. Although similarities 
in histologic changes do not necessarily 
refl ect similarities in functional altera-
tions, taken together with the other 
observations of Ayus et al. they do sug-
gest that “hypoxia appears to be a major 
co-morbidity factor in the outcome of 
patients with hyponatremic encephalo-
pathy.”9 In support of this conclusion is 
a large metaanalysis that was reported at 
the 2005 American Society of Nephrology 
meeting (A.I. Arieff , M.S. Etheridge and 
E.L. Bradley, J Am Soc Nephrol 16: 44A, 
2005) of 344 patients with symptomatic 
hyponatremia over a 30-year period that 
concluded that associated hypoxia was a 
major determinant of adverse outcome 
and that mortality was 3.5 times greater 
in those patients who had their serum 
sodium concentration corrected at rates 
below 0.55 mequiv. per liter per hour.10
So what is the clinician to conclude 
from all these studies when faced with 
a severely hyponatremic patient? Th ere 
is no question that many asymptomatic 
patients with normal arterial oxygen 
saturation and severe hyponatremia do 
well without rapid correction of their 
serum sodium concentration; how-
ever, it is now clear that symptomatic 
hyponatremic patients, especially if 
they are female and hypoxic with arte-
rial partial pressure of oxygen below 
70 mm Hg, should receive rapid cor-
rection of their sodium concentration 
to safe levels. Th us, to use Berl’s color-
ful choice of words,4 one must conclude 
that we are damned if we don’t, or at 
least the patient is. 
Now comes the important question of 
how to administer the sodium, and at 
what rate it will decrease the very high 
mortality associated with the combi-
nation of hypoxia and hyponatremia. 
The literature supports the view that 
the rate of correction should be at least 
0.55 mequiv. per liter per hour. It is 
impractical in an acute hospital setting 
to try to calculate accurately how much 
sodium to give. First, it is diffi  cult to 
obtain accurate patient weights, good 
estimates of total body water, and esti-
mates of bone weight (approximately 
43% of body sodium is in functionally 
non-exchangeable bone pool); and sec-
ond, although administered sodium 
freely moves between plasma, inter-
stitium, and, thus, lymph, the rate of 
sodium equilibration between intrac-
ellular compartments, connective tis-
sue, and so on is slower. Nevertheless, 
some guidelines can be suggested. I 
have recommended ordering 250 ml of 
3% NaCl (514 mequiv. per liter), giv-
ing 50 ml by intravenous push (which 
should raise the plasma sodium con-
centration by 1–2 mequiv. per liter), 
and letting the remaining 200 ml drip 
for the next 4–6 hours. Th is generally 
raises the serum sodium concentration 
by 8–10 mequiv. per liter and gets the 
patient out of the acute neurologic dan-
gers of hyponatremia. Th is will then buy 
time in which to plan how to correct the 
remaining diff erence in sodium concen-
tration. I advise not to raise the sodium 
concentration much over 120 mequiv. 
per liter in the fi rst 24 hours and then 
to correct the remaining defi cit at a rate 
that improves serum concentration 
each 24 hours by 50% of the desired 
fi nal sodium concentration. One of the 
practical issues I have faced in the emer-
gency room is the unavailability of 3% 
NaCl or an enormous delay in getting it 
there. Given the lack of any evidence to 
the contrary, I have recommended push-
ing an ampoule of NaHCO3 in these 
circumstances (an ampoule usually con-
tains either 44 or 50 mequiv. NaHCO3); 
this will allow time to get the 3% NaCl 
delivered. I feel that the weight of the 
literature supports initiation of the cor-
rection of the osmolality as soon as it is 
feasible. I make these same therapeutic 
recommendations also for patients who 
have symptomatic hyponatremia but 
normal oxygenation. Although these 
patients do not have the same high risk 
of mortality as hypoxic patients, they 
nevertheless are at increased risk of 
dying. If, on the other hand, the patient 
is hypoxic for any reason (central res-
piratory depression secondary to brain 
edema, pneumonia, or any other cause), 
or if the patient’s arterial oxygen begins 
to drop during the course of treatment, 
then he or she should be hospitalized 
in an intensive care unit and intubated 
sooner rather than later if the arterial 
partial pressure of oxygen cannot be 
raised to over 70 mm Hg by an increase 
in fraction of inspired oxygen (FIO2).
If comorbid conditions are recognized 
early in symptomatic hyponatremic 
patients, and if treatment is initiated rap-
idly, then we can reasonably expect to 
decrease the very high mortality other-
wise reported. We should not dismiss the 
possibility of CPM, but our therapeutic 
approaches should not be paralyzed by 
fear that CPM will develop.
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Time to consider ACE insertion/
deletion genotypes and individual 
renoprotective treatment in 
diabetic nephropathy?
PK Jacobsen,1 L Tarnow1 and H-H Parving1,2
One reason for the inadequacy of current renoprotective therapy and 
the persistent poor renal prognosis in diabetic nephropathy is the large 
interindividual variation in response to treatment. Genetic as well as 
non-genetic factors are known to influence treatment efficacy. This 
Commentary summarizes the impact of the angiotensin-converting 
enzyme (ACE) insertion/deletion polymorphism in the ACE gene on 
initiation and progression of diabetic nephropathy.
Kidney International (2006) 69, 1293–1295. doi:10.1038/sj.ki.5000283
Antihypertensive treatment has greatly 
improved the renal prognosis and survival 
of diabetic patients with nephropathy over 
the past few decades.1 More patients die 
of other causes, primarily cardiovascu-
lar, with well-preserved kidney function. 
However, despite therapy targeting ele-
vated blood pressure, albuminuria, hyper-
glycemia, and lipid abnormalities, patients 
with diabetic nephropathy still on average 
have a rate of decline in renal function 
three to six times that seen in individuals 
without renal disease.1,2 Consequently, 
diabetic nephropathy is still the most com-
mon cause of end-stage renal disease in the 
Western world. One reason for the inad-
equacy of current renoprotective therapy 
and the persistent poor renal prognosis 
is the large interindividual variation in 
response to fi rst-line therapy including 
drugs blocking the renin–angiotensin–
aldosterone system, as is demonstrated 
by the wide range in loss of glomerular 
filtration rate (GFR) in these subjects. 
Indeed, this ranges from 0 to 24 ml per 
minute per year during treatment.1,2 Well-
known non-genetic risk factors, namely 
elevated blood pressure, albuminuria, 
poor glycemic control, and hypercholes-
terolemia, explain about 30%–50% of this 
variation.1,2 Characterization of additional 
risk factors is the key to understanding the 
progression of diabetic nephropathy, to 
identifying high-risk individuals, and to 
improving treatment and overall progno-
sis. Besides the non-genetic factors, drug 
responses are also known to be infl uenced 
by inherited factors;3 this fi eld is known as 
pharmacogenomics.3 Th e basic concept is 
simple: a drug interacts with its target, for 
instance an enzyme or a receptor. When 
genetic alteration leads to modifi ed target 
availability or function, the drug response 
is modifi ed as well. However, this con-
cept also involves more complex relations 
such as interplay between several genetic 
sites during therapy and the direct eff ects 
of drugs on gene transcription. Basically, 
pharmacogenomics is the integrated 
eff ects of the genome on drug response. In 
this issue, So et al.4 provide more evidence 
supporting the importance of pharmacog-
enomics in diabetic patients by reporting 
an impact of the angiotensin-converting 
enzyme (ACE) insertion/deletion poly-
morphism in the renin–angiotensin sys-
tem on response to ACE inhibition in 2089 
Chinese type 2 diabetic patients with vari-
ous degrees of albuminuria.
Activation of the renin–angiotensin–
aldosterone system is important in the 
initiation and progression of diabetic 
nephropathy.1 Th e ACE insertion (I)/dele-
tion (D) polymorphism infl uences the 
systemic and renal activity of the renin–
angiotensin system, as patients carrying 
the D allele have increased systemic and 
renal ACE levels, whereas patients with the 
II genotype have the lowest ACE concen-
trations.1 A recent metaanalysis of 14 727 
diabetic patients included in case-control 
studies from 1994 to 2004 confi rms a sta-
tistically signifi cant protective role of the 
II genotype in the development of diabetic 
nephropathy;5 the eff ect was most pro-
nounced in Asians with type 2 diabetes, 
followed by Caucasians with types 1 and 
2 diabetes.5 Th e relation between the ACE 
I/D polymorphism and progression of 
diabetic nephropathy has been studied 
during the past 10 years. Minimal data 
exist on the impact of ACE gene poly-
morphism during the natural course of 
diabetic nephropathy without any anti-
hypertensive treatment. In 59 normoten-
sive type 1 diabetic patients with diabetic 
nephropathy and stable renal function 
(decline in GFR of about 1 ml per minute 
per year), we found no relation between 
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